Cytoreductive surgery after recurrent epithelial ovarian cancer and at other timepoints

作     者：Paolo Sammartino Tommaso Cornali Marialuisa Framarino dei Malatesta Pompiliu Piso Paolo Sammartino;Tommaso Cornali;Marialuisa Framarino dei Malatesta;Pompiliu Piso

作者机构：Department of Surgery Pietro Valdoni Policlinico Umberto I 00161 Rome Italy Department of Gynecological Obstetrical and Urological Sciences Policlinico Umberto I 00161 Rome Italy Department of General Surgery Barmherzige Brüder Hospital 93049 Regensburg Germany 

出 版 物：《World Journal of Obstetrics and Gynecology》 (世界妇产科杂志)

年 卷 期：2013年第2卷第4期

页      面：101-107页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Ovarian cancer Cytoreductive surgery Re-current ovarian cancer Secondary cytoreduction Sur-gery for Platinum sensitive ovarian cancer Surgery for Platinum resistant ovarian cancer 

摘      要：In this descriptive review we look at the role of surgery for advanced ovarian cancer at other timepoints apart from the initial cytoreduction for front-line therapy or interval cytoreductive surgery after neoadjuvant chemotherapy. The chief surgical problem to face after primary treatment is recurrent ovarian cancer. Of far more marginal concern are the second-look surgical procedures or the palliative efforts intended to resolve the patient s symptoms with no curative intent. The role of surgery in recurrent ovarian cancer remains poorly defi ned. Current data, albeit from non-randomized studies, nevertheless clearly support surgical cytoreduction in selected patients, a rarely curative expedient that invariably yields a marked survival advantage over chemotherapy alone. Despite these fi ndings, some consider it too early to adopt secondary cytoreduction as the standard care for patients with recurrent ovarian cancer and a randomized study is needed. Two ongoing randomized trials(Arbeitsgemeinschaft Gynkologische Onkologie-Desktop Ⅲ and Gynecologic Oncology Group 213) intend to verify the role of secondary cytoreduction for platinum-sensitive ovarian cancer compared with chemotherapy considered as standard care for these patients. We await the results of these two trials for a defi nitive answer to the matter.